Table 3 Relative vaccine efficacies (rVE) of ARCT-154 vs. ChAdOx1-S against confirmed protocol-defined COVID-19 (mITT)
Total no. of persons | Cumulative follow-up in person-yrs | No. with event | Total no. of persons | Cumulative follow-up in person-yrs | No. with event | Relative vaccine efficacy (95% confidence interval) | |
|---|---|---|---|---|---|---|---|
ARCT-154 | ChAdOx1-S | ||||||
Any severity of confirmed protocol-defined COVID-19 in adults (≥18 years) | |||||||
Assessed from Day 36 to Day 92 | 1165 | 183.5 | 20 | 1156 | 183.8 | 28 | 30.7% (−23.0–58.4) |
Assessed from Day 36 to Day 211 | 1165 | 518.8 | 205 | 1156 | 501.5 | 245 | 19.3% (2.8–32.9) |
Assessed from Day 36 up to Day 394 (study end) | 1165 | 965.7 | 218 | 1156 | 922.4 | 262 | 19.8% (4.0–33.0) |
Any severity of confirmed protocol-defined COVID-19 by age group up to Day 394 | |||||||
≥18 years to <50 years of age | 503 | 424.9 | 88 | 486 | 393.1 | 104 | 21.6% (−4.2–41.0) |
≥50 years of age | 662 | 540.7 | 130 | 670 | 529.4 | 158 | 18.3% (−3.0–35.30) |
≥60 years of age | 319 | 267.1 | 51 | 321 | 260.3 | 71 | 29.8% (−0.7–51.0) |
≥65 years of age | 166 | 137.0 | 28 | 160 | 127.8 | 40 | 33.5% (−7.8–59.0) |
≥70 years of age | 71 | 60.5 | 11 | 68 | 53.7 | 18 | 43.5% (−20.0–73.4) |
